AAOMS Annual Meeting

After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.

After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.

After clinical trials demonstrated a superior overall survival compared with standard care, the US Food and Drug Administration granted full approval to Blincyto.

The US Food and Drug Administration recently approved a new oral treatment for adult and pediatric patients with sickle cell disease.

The US Food and Drug Administration recently approved a new oral treatment for adult and pediatric patients with sickle cell disease.

The US Food and Drug Administration recently approved a new oral treatment for adult and pediatric patients with sickle cell disease.

Following an FDA-issued withdrawal request, an abuse-deterrent opioid will be removed from the market.

Following an FDA-issued withdrawal request, an abuse-deterrent opioid will be removed from the market.

Following an FDA-issued withdrawal request, an abuse-deterrent opioid will be removed from the market.

After several studies demonstrated its efficacy, the FDA expanded the approval of the DigniCap Cooling System to prevent hair loss during chemotherapy to other cancer patients.